Table of Contents

Section I: Basic Psychopharmacology Chapter 1: A New Psychopharmacology Nomenclature Chapter 2: Fundamentals of Neurobiology Chapter 3: Fundamental Psychotropic Drug Structures and Mechanisms Section II: Clinical Research Concepts for Psychopharmacology Chapter 4: The Limitations of Clinical Experience Chapter 5: Evidence-based Medicine: Pro and Con Chapter 6: Maintenance Treatment Designs: "Enriched," But Not Better Chapter 7: Negative Studies: The Failure to Know What Isn't Known Chapter 8: Side Effects and Generalizability: Beyond p-values Section III: Clinical Psychopharmacology of Drug Classes Chapter 9: Monoamine Agonists ("Antidepressants"), Including Dopamine Agonists ("Stimulants") Chapter 10: Dopamine Blockers ("Antipsychotics") Chapter 11: Second Messenger Modifiers ("Mood Stabilizers") Chapter 12: Gabaergic Agonists ("Anxiolytics") Chapter 13: Other Agents (Glutamate Antagonists, Antihistamines, Melatonin Agonists, and Others) Chapter 14: Drug Class Summaries and Dosing Guidelines Chapter 15: Index of Selected Commonly Used Drugs with Brief Summaries Section IV: Clinical Psychopharmacology of Diseases and Syndromes Chapter 16: Hippocratic Psychopharmacology: A Non-DSM Approach to Practice Chapter 17: Beyond Symptoms: Diagnostic Validators Chapter 18: The Concept of a Diagnostic Hierarchy Chapter 19: Treatment of Affective Illnesses Chapter 20: Anxiety Conditions Chapter 21: Treatment of Personality Chapter 22: Schizophrenia and Schizoaffective Conditions Chapter 23: Addictions Chapter 24: PTSD Section V: Special Topics Chapter 25: Carcinogenicity of Psychotropic Drugs Chapter 26: Seasonal Affective Illness Chapter 27: Suicide Chapter 28: Children Chapter 29: Older Persons Chapter 30: Women Chapter 31: Ethnic and Racial Groups Chapter 32: Psychopharmacology in Medical Illnesses Chapter 33: Polypharmacy Chapter 34: Cultural Aspects of Psychopharmacology Chapter 35: Treatment versus Enhancement Chapter 36: The Pharmaceutical Industry Chapter 37: Drug Discovery: Future Treatments Section VI: The Art of Psychopharmacology Chapter 38: The Diagnostic Interview Chapter 39: The "Med Check" Chapter 40: The Placebo Effect Chapter 41: Legal Aspects of Psychopharmacology Practice Chapter 42: Psychology of Psychopharmacology Chapter 43: Innovation in Clinical Practice Chapter 44: Clinical Cases Chapter 45: Curbside Consults: Questions and Answers Chapter 46: Key Research Studies in Clinical Psychopharmacology Chapter 47: Historical Insights in Psychopharmacology Chapter 48: Reflections on the Art of Psychopharmacology Chapter 49: Ten Fallacies and Ten Truths of Psychopharmacology - Explained Appendices Appendix I: Mixed States Appendix II: Bipolar or Borderline? Appendix III: ADD in Children and Adults Appendix IV: Schizoaffective Illness

Promotional Information

Winner of the 2020 Prose Award for Excellence in Clinical Psychology by the Association of American Publishers

About the Author

S.Nassir Ghaemi, MD, MPH, is a Professor of Psychiatry and Pharmacology at Tufts University School of Medicine, and a Lecturer on Psychiatry at Harvard Medical School in Boston, Massachusetts. He is also Director of Translational Medicine-Neuroscience at Novartis Institutes for Biomedical Research in Cambridge, Massachusetts. Dr. Ghaemi has been active in clinical psychopharmacology practice and research for over two decades, with specialization in depression and bipolar illness. He holds degrees in philosophy and public health, and is a highly published scientific investigator.

Reviews

"This book will be useful to readers not only because it provides information and rationales on how to treat psychiatric disease, but also because it attempts to cover these topics in a unique way that other books have not." -- Chad R Percifield, Doody's Publishers Club